Carboplatin combined with arsenic trioxide versus carboplatin combined with docetaxel treatment for LACC: A randomized, open-label, phase II clinical study.

PURPOSE

This study compared the efficacy and safety of carboplatin combined with arsenic trioxide versus carboplatin combined with docetaxel in treating locally advanced cervical cancer (LACC).

METHODS

A total of 48 patients were enrolled between January 2019 and December 2022 and randomly assigned to the experimental group (carboplatin + arsenic trioxide, = 24) or control group (carboplatin + docetaxel, = 24). The clinical efficacy, adverse reactions, and serological markers were analyzed.

RESULTS

There was no significant difference in baseline characteristics or total effective rates between the two groups (72.22% vs 68.42%, > 0.05). Both groups showed significant reductions in serum squamous cell carcinoma antigen levels after chemotherapy ( < 0.05), but no significant difference was observed between groups (6.00 ± 11.36 ng/mL vs 8.42 ± 12.17 ng/mL, > 0.05). Additionally, there was no significant difference in the incidence of adverse reactions ( > 0.05).

CONCLUSION

Arsenic trioxide combined with carboplatin as a preoperative neoadjuvant chemotherapy for LACC is not worse than docetaxel combined with carboplatin in terms of short-term efficacy and safety during the treatment of LACC.